Qiagen N.V. (USD) Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Qiagen N.V. (USD) Active

Hulsterweg 82, Venlo, LI, NL, 5912 PL

Stock Price USD

Price Change

Last Dividend USD

A-

Latest Rating

QGEN's stock peer is ALGN (Align Technology, Inc.)

QGEN's stock peer is BAX (Baxter International Inc.)

QGEN's stock peer is BMRN (BioMarin Pharmaceutical Inc.)

QGEN's stock peer is CRL (Charles River Laboratories International, Inc.)

QGEN's stock peer is ENSG (The Ensign Group, Inc.)

QGEN's stock peer is EXEL (Exelixis, Inc.)

QGEN's stock peer is HIMS (Hims & Hers Health, Inc.)

QGEN's stock peer is ICLR (ICON Public Limited Company)

QGEN's stock peer is RVTY (Revvity, Inc.)

QGEN's stock peer is TECH (Bio-Techne Corporation)

Healthcare Medical - Diagnostics & Research

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

100%

Dcf Rating

80%

Return On Equity

100%

Return On Assets

40%

Debt To Equity

40%

Price To Earnings

60%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2026-07-07	2026-07-14	0.35	6.70 %	Semi-Annual
2026-01-08		2.29	4.73 %	Semi-Annual
2025-07-02	2025-07-10	0.25	3.18 %	Semi-Annual
2025-01-29	2025-01-29	1.26	2.96 %	Annual
2024-01-31	2024-01-31	1.28	3.19 %	Special

Recent News

QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications. As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabi.

2026-06-15 01:30:00